A5010503529- Autoimmune and Inflammatory Disorders Research
- Adolescent and Pediatric Healthcare
- Rheumatoid Arthritis Research and Therapies
- Kawasaki Disease and Coronary Complications
- Inflammasome and immune disorders
- Cardiac Imaging and Diagnostics
- Salivary Gland Disorders and Functions
- Advanced MRI Techniques and Applications
- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Cardiovascular Function and Risk Factors
- Immunodeficiency and Autoimmune Disorders
- Psoriasis: Treatment and Pathogenesis
- Acute Lymphoblastic Leukemia research
- Diabetes and associated disorders
- Spondyloarthritis Studies and Treatments
- Exercise and Physiological Responses
- Sarcoidosis and Beryllium Toxicity Research
- Skin Diseases and Diabetes
- Bacterial Infections and Vaccines
- Autoimmune Bullous Skin Diseases
- Child and Adolescent Health
- Vasculitis and related conditions
- Diversity and Career in Medicine
- Medical Education and Admissions
Osaka Rosai Hospital
2022-2025
Osaka University of Pharmaceutical Sciences
2017-2024
Osaka Medical and Pharmaceutical University
2006-2021
Japan Pediatric Society
2020
Tokai University Hachioji Hospital
2008
Municipal Hirakata City Hospital
2006
Objectives To collect clinical information and NOD2 mutation data on patients with Blau syndrome to evaluate their prognosis. Methods Fifty mutations were analysed. The activity of each mutant was evaluated in HEK293 cells by reporter assay. Clinical collected from medical records through the attending physicians. Results study population comprised 26 males 24 females aged 0–61 years. Thirty-two cases sporadic, 18 familial 9 unrelated families. Fifteen different identified, including 2 novel...
This study aimed to determine the influence of tocilizumab (TCZ) in modifying clinical and laboratory features macrophage activation syndrome (MAS) complicating systemic juvenile idiopathic arthritis (s-JIA). Furthermore, we assessed performance 2016 MAS classification criteria for patients with s-JIA-associated while treated TCZ.A panel 15 pediatric rheumatologists conducted a combination expert consensus analysis real patient data. Clinical 12 TCZ-treated 18 untreated were evaluated....
Juvenile idiopathic arthritis (JIA) is the most common disease in pediatric rheumatism. There no specific symptom or examination finding for JIA, and diagnosis made by exclusion differentiation. Because non-pediatric rheumatologists are sometimes involved medical care, 'proposal JIA guidance on treatment primary care pediatricians rheumatologists' was first published 2007. In these 10 years, a number of new findings pathophysiology have been published; therefore, we propose this 2018th...
Although there are many reports on Juvenile Idiopathic arthritis-associated uveitis (JIA-U) from various countries, especially Europe and North America, few Asia. Our aim was to investigate the epidemiology, characteristics predictors of JIA-U in Japan.Data were retrospectively collected 726 patients with JIA medical records as April 2016 at 15 centers specialized pediatric rheumatic diseases. Of these, further investigated for specific this manifestation.The prevalence 6.1% examined....
ABSTRACT Objectives To assess the safety and effectiveness of baricitinib treatment for rheumatoid arthritis (RA) in real-world clinical practice. Methods This ongoing all-case post-marketing surveillance study (starting September 2017) includes all patients with RA treated Japan. Safety (disease activity) were assessed 24 weeks. Results analyses to February 2021 included 4731 (initial dose: 4 mg/day, n = 3058; 2 1661; other, 12); 1059 (22.38%) ≥75 years 3362 (71.06%) previously received...
Evaluate tofacitinib real-world safety/effectiveness in patients with rheumatoid arthritis Japan a 3-year all-case post-marketing surveillance study. All who initiated (07/30/2013-12/03/2017) were registered Japan. Serious infections/malignancy/mortality incidence compared active after >8 mg methotrexate/week for ≥3 months received or other drugs (control: methotrexate/other disease-modifying antirheumatic drugs/immunosuppressants). Disease activity was assessed over 3 years. The adherent...
<i>Objective:</i> We investigated the role of antioxidants in airway hyperresponsiveness to acetylcholine using young asthma model mice, which were sensitized and stimulated with ovalbumin. <i>Methods:</i> The mice had been fed either a normal diet, an α-tocopherol-supplemented diet or probucol-supplemented 14 days before first sensitization. They immunized antigen at intervals 12 and, starting from 10 after second immunization, they exposed 3 times every 4th day...
Mevalonate kinase deficiency (MKD), a rare autosomal recessive autoinflammatory syndrome, is caused by disease-causing variants of the mevalonate (MVK) gene. A national survey was undertaken to investigate clinical and genetic features MKD patients in Japan.The identified ten with MKD. Clinical information laboratory data were collected from medical records direct interviews patients, their families, attending physicians. Genetic analysis measurement MVK activity urinary excretion mevalonic...
ABSTRACT Objectives To assess safety of baricitinib in Japanese patients with rheumatoid arthritis (RA) real-world clinical practice. Methods This all-case postmarketing surveillance study included initiating for RA from September 2017 to April 2019. Treatment duration was recorded. Safety data were collected up 3 years initiation (up 4 weeks postdiscontinuation discontinuing patients). Results analyses 4720 patients; 2580 (54.7%) ≥65 old. Baricitinib persistence rate 45.4% (3-year...
To validate whether the 2016 American College of Rheumatology/European League Against Rheumatism classification criteria macrophage activation syndrome (MAS) complicating systemic juvenile idiopathic arthritis (JIA) is practical in real world.A combination expert consensus and analysis patient data was conducted by a panel 15 pediatric rheumatologists. A total 65 profiles comprised 18 patients with JIA-associated MAS 47 active JIA without evidence MAS. From these profiles, 10 points for...
There are a considerable number of pediatric patients with Sjögren's syndrome (SS); however, SS is generally considered rare among children. Pediatric report fewer sicca symptoms; therefore, many under-diagnosed and cannot access appropriate medical management. Therefore, we propose newly developed guidance for the diagnosis, treatment, management SS, including epidemiology, clinical features, diagnostic examination methodology. The aim this was to standardize care in Japan, published...
This nationwide study aimed to reveal the prevalence of ankylosing spondylitis (AS), non-radiographic axial spondyloarthritis (nr-ax SpA), and positivity rate human leukocyte antigen (HLA) among such patients in Japan.The first survey was conducted 2221 randomly selected facilities (26.3%) September 2018, where with AS/nr-ax SpA were taken care from January December 2017. We estimated total number these using response extraction rates. A second 117 (49.8%) assess for HLA-B27 clinical...
To investigate efficacy and safety of intravenous abatacept in Japanese patients with active polyarticular-course juvenile idiopathic arthritis (pJIA). In this phase III, open-label, multicenter, single-arm study, pJIA aged 4–17 years who failed ≥1 biologic or methotrexate received weight-tiered (< 75 kg: 10 mg/kg; 75–100 750 mg; > 100 1000 mg) at Weeks 0, 2, 4, every 4 weeks thereafter. The study comprised a short-term period (16 weeks) ongoing long-term period. Primary endpoint: Week 16...
Introduction: Systemic juvenile arthritis -a rare chronic disease.Registerit's an important tool to monitor the effectiveness and safety of GIBP.Objectives: Our aim was study features drug therapy children with systemic idiopathic (sJIA) Methods: We conducted a retrospective data analysis included in Register sJIA cases, for period from 2002 2015 Results: The indicators 384 are studied.Prior diagnosis verification, all patients were prescribed intake antipyretic agents, 98%...
Abstract Objectives To clarify how pediatric rheumatologists treat systemic juvenile idiopathic arthritis (s‐JIA) associated macrophage activation syndrome (MAS) in the real world and to assess efficacy safety of dexamethasone palmitate (DEX‐P) treatment s‐JIA‐associated MAS. Methods This multicenter, retrospective study was conducted at 13 rheumatology institutes Japan. included 28 patients with Clinical findings, such as details adverse events, were evaluated. Results Methylprednisolone...
Objective: We researched the findings of musculoskeletal ultrasound sonography (MSUS) on primary Sjogren's syndrome in childhood (pSS-C) with articular manifestations. The correlation rheumatoid factor (RF) and anti-cyclic citrullinated peptide antibody (ACPA) were investigated to evaluate usefulness MSUS their prognosis. Method: objective patients are pSS-C cases who visited our hospital complaining joint pain and/or swelling for whom was performed. Result: Eight included 6 female 2 male, 5...
Although epidemiological surveys of paediatric rheumatic diseases in Japan have been conducted, they were single with no continuity. This is the first report Pediatric Rheumatology Association registry database, which was established to continuously collect data for diseases.Pediatric International Collaborate Unit Registry version 2 (PRICUREv2) a database by Japan. The analysed age onset, time diagnosis, sex differences, seasonality, and other factors.Our showed same trend regarding rates...
Background: An all-case post marketing surveillance (PMS) of baricitinib (Bari), that started in Sep 2017, collects safety and effectiveness for the first 24 wks treatment continues to collect serious adverse events (SAEs) 3 yrs. Objectives: To evaluate Bari RA patients (pt) clinical practice. Methods: We report pt baseline demographics (AEs) up pts whose case files 24-wk data were completed as Jun 2020. Results: Data from 3445 analyzed (females=80%, mean age=64yr, duration 12yr). dose...
<h3>Background</h3> Previous studies including a systematic literature review revealed clinical manifestations and laboratory features of systemic juvenile idiopathic arthritis (s-JIA) associated macrophage activation syndrome (MAS) could be modified in patients treated with tocilizumab (TCZ) <sup>1,2</sup>. <h3>Objectives</h3> To clarify whether TCZ modifies s-JIA MAS, to assess performance the 2016 MAS classification criteria for while real world. <h3>Methods</h3> A combination expert...
<h3>Background</h3> Tocilizumab (TCZ) was approved for systemic juvenile idiopathic arthritis (sJIA) as an intravenous formulation in 2008 after its effectiveness and safety were shown a world-leading clinical trial performed Japan 2002–2008. <h3>Objectives</h3> This study aimed to understand the long-term prognosis of patients participating phases II (Study MRA011JP), III MRA316JP), III/IV MRA324JP). There 149 participants trial. <h3>Methods</h3> Information on eligible obtained from 12...